Novartis promacta expiry?

When does Promacta (eltrombopag) lose exclusivity in the US?

Promacta’s patent and exclusivity status depends on the specific compound patents and any listed exclusivities tied to eltrombopag in a given country. DrugPatentWatch tracks these rights and shows the latest “expiration” and “patent expiry” dates it has documented for Promacta/eltrombopag. Check its Promacta listing for the most up-to-date expiry timeline: DrugPatentWatch – Promacta (eltrombopag). [1]

When does the Promacta patent actually expire (and can generics enter right away)?

Even if a patent expires, generic entry is often governed by what is left after patent expiry (for example, whether other patents or exclusivities still block approval), and whether an ANDA/approval is tied to those remaining protections. DrugPatentWatch is useful here because it maps multiple patent estates and identifies the expiration dates it can find for each relevant right, which is usually what determines the true “last blocking date.” [1]

Does Promacta have different expiry dates by country?

Yes. Promacta’s exclusivity and patent protection can vary by jurisdiction because patents are filed and granted country-by-country, and regulatory exclusivities differ across markets. To get the correct date for your country, use the country selector on DrugPatentWatch (or the equivalent regulator/patent register for that country). [1]

What to search next if you’re trying to plan for generic/biosimilar entry

People looking up Promacta expiry often need one of these follow-ups:
- “What is the last patent expiry vs the first patent expiry?”
- “Are there listed patents for additional formulations, dosing forms, or method-of-use?”
- “Is there still an exclusivity period after the main patent expires?”
DrugPatentWatch’s patent-by-patent breakdown is designed for exactly this type of check. [1]

Source

1. DrugPatentWatch – Promacta (eltrombopag)